Sarasota Surgeons Performed Dual Heart Procedure
Sarasota Memorial patients underwent combined valve replacement and stroke-prevention procedures in a single surgery.
Updated on Oct. 13, 2026 in Heart Disease
Live Poll
Do you trust that new medical device combinations will improve long-term heart health?
Surgeons at Sarasota Memorial Hospital successfully implanted a TRIFORMIS RESILIA valve and an ECLIPTIS system during a single operation to address multiple heart issues. The dual-procedure approach aims to treat a diseased valve and reduce stroke risk in one visit.
Why it matters
Combining these two cardiac interventions in a single surgery allows patients to receive necessary care for valve disease and stroke prevention without the recovery time and risks associated with separate operations. This approach simplifies the surgical experience for those requiring multiple cardiac repairs.
Sarasota Memorial Hospital surgeons completed a combined procedure using the FDA-approved TRIFORMIS RESILIA valve and the ECLIPTIS system. While this case represents a successful single-operation approach, broader long-term clinical data on these combined implants remains under evaluation.
The players
Dr. Jonathan Hoffberger
A surgeon at Sarasota Memorial Hospital who performed the dual-implant procedure.
Sarasota Memorial Hospital
A medical center in Sarasota providing cardiac care and surgical services.
Dr. Jeffrey Sell
A surgeon who performed ECLIPTIS implants on additional patients at the hospital.
Dr. Kristen Walker
A surgeon who performed ECLIPTIS implants on additional patients at the hospital.
The details
The procedure replaces a diseased tricuspid valve with the TRIFORMIS RESILIA valve, a device approved for this specific anatomical position. Simultaneously, the ECLIPTIS system is deployed to close the left atrial appendage, a structure linked to blood clot formation and stroke risk. By performing these tasks together, surgeons avoid the historical necessity of adapting valves designed for other heart chambers while addressing multiple complications in one cardiac cycle.
Timeline
May 2026: The TRIFORMIS RESILIA valve received FDA approval.
June 2026: The ECLIPTIS system received FDA clearance.
October 13, 2026: Sarasota Memorial Hospital announced the completed procedures.
Health Landscape
This procedure marks a departure from the historical practice of off-label valve adaptation where surgeons had to modify devices designed for other heart positions. It reflects a shift toward using condition-specific implants to improve the precision of cardiac repair.
If you are managing tricuspid valve disease or stroke risk, these procedures are worth discussing with your cardiologist to understand if combined surgical options are relevant to your treatment plan. Determining the right care setting for specialized cardiac implants should always be handled by your physician.
The takeaway
Advancements in cardiac device technology are increasingly allowing surgeons to address multiple heart conditions in a single, efficient operation. If you have been diagnosed with valve disease or require stroke prevention measures, talk to your doctor about the most effective, consolidated surgical path.
Further reading
Learn more about the latest surgical advancements in our guide to Heart Disease.
Source note: This article includes information reported by Mysuncoast.
Live Poll
Do you trust that new medical device combinations will improve long-term heart health?
